Curative Biotechnology, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Curative Biotechnology, Inc. (NASDAQ: CUBT) develops and commercializes novel biological therapeutics for treating age-related diseases, including Alzheimer's disease and type 1 diabetes mellitus. The company focuses on innovative product candidates such as EB-05, a neuroprotective small molecule peptide targeting amyloid precursor protein processing for Alzheimer's; EB-101, an allogeneic engineered NK cell therapy for solid tumors; and iPSC-derived therapies aimed at restoring insulin production for diabetes. Its pipeline includes gene- and cell-based therapies designed to address unmet medical needs in neurodegeneration and metabolic disorders; research and development services; and preclinical studies conducted through contract research organizations. Founded in 2014 and headquartered in Boca Raton, Florida, Curative Biotechnology operates primarily in the United States with a focus on the biotechnology sector, targeting patients with age-related and chronic conditions through clinical-stage development. The company serves pharmaceutical partners, healthcare providers, and research institutions in North America. In recent developments, Curative Biotechnology completed a reverse stock split in 2024 to maintain its NASDAQ listing compliance and announced positive preclinical data for its diabetes program in mid-2025. It secured non-dilutive funding through grants and partnerships for NK cell therapy advancement, expanded its intellectual property portfolio with new patents on neuroprotective peptides, and initiated Phase 1 preparations for EB-05 following FDA feedback in late 2024. These strategic moves support pipeline progression amid ongoing capital raises and operational efficiencies.
Curative Biotechnology Advances Translational Ophthalmology Program Through PennVet Research Agreement
Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting
Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting
Curative Biotechnology Announces Canadian Patent Allowance
Curative Biotechnology, Inc. Announces Letter to Shareholders
Curative Biotechnology, Inc. Engages Golden Eagle Capital Advisors, Inc. as Exclusive Agent and Strategic Advisor
Curative Biotechnology, Inc. Announces Nomination of Dr.
Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors
Curative Biotechnology, Inc. Announces Nomination of Dr.
Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors
Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors
Curative Biotechnology, Inc. Announces Nomination of Dr. Jeffrey Liebmann to Board of Directors
CURATIVE BIOTECHNOLOGY ANNOUNCES DR. CATHERINE SOHN AS SPECIAL ADVISOR TO BOARD AND CEO
CURATIVE BIOTECHNOLOGY ANNOUNCES IMT504 LICENSE FOR DEVELOPMENT OF PROPRIETARY NEXT-GEN COVID-19 VACCINE
Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine
Curative Biotechnology, Inc. Announces Addition of Dr. Nicholas Boulis to Scientific and Clinical Advisory Board